SuperworthAdial Pharmaceuticals EPS ADIL
Diluted earnings per share by quarter and over the last twelve months, from 2017.
- Last 12 months, to Jun 30, 2026
- −$16.56
- Latest quarter, Q2 FY26
- −$11.25
- Fiscal year 2025
- −$16.96
Adial Pharmaceuticals' earnings per share was −$16.56 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$11.25.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$16.96 | n/a |
| FY2024 | −$87.00 | n/a |
| FY2023 | −$95.00 | n/a |
| FY2022 | −$325.50 | n/a |
| FY2021 | −$656.25 | n/a |
| FY2020 | −$537.50 | n/a |
| FY2019 | −$562.50 | n/a |
| FY2018 | −$1431.25 | n/a |
| FY2017 | −$212.50 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$11.25 | n/a | −$16.56 | |
| Q1 FY26 | −$1.48 | n/a | −$9.92 | |
| Q4 FY25 | −$1.83 | n/a | −$16.96 | |
| Q3 FY25 | −$2.00 | n/a | −$23.13 | |
| Q2 FY25 | −$4.61 | n/a | −$30.63 | |
| Q1 FY25 | −$8.52 | n/a | −$40.77 | |
| Q4 FY24 | −$8.00 | n/a | −$87.00 | |
| Q3 FY24 | −$9.50 | n/a | −$99.75 | |
| Q2 FY24 | −$14.75 | −161% | −$119.75 | |
| Q1 FY24 | −$54.75 | n/a | −$81.00 | |
| Q4 FY23 | −$20.75 | n/a | −$95.00 | |
| Q3 FY23 | −$29.50 | n/a | −$144.00 |
Against its peers
Companies in Drug Manufacturers - General nearest Adial Pharmaceuticals' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| ADILAdial Pharmaceuticals | −$16.56 | |
| ATNMActinium Pharmaceuticals | $0.36 | |
| SPROSpero Therapeutics | $0.11 | |
| LFVNLifevantage | $0.40 | −46% a year |
| Peer median | $0.36 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Adial Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.